Compare CANF & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | UGRO |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 1.8M |
| IPO Year | 2011 | 2018 |
| Metric | CANF | UGRO |
|---|---|---|
| Price | $3.72 | $3.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | ★ 631.0K | 62.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,008,850.00 |
| Revenue This Year | $461.72 | $98.41 |
| Revenue Next Year | $290,391.28 | $23.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.11 |
| 52 Week High | $10.40 | $4.50 |
| Indicator | CANF | UGRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 67.65 |
| Support Level | $0.60 | $0.28 |
| Resistance Level | $4.74 | $4.50 |
| Average True Range (ATR) | 0.71 | 0.25 |
| MACD | -0.17 | -0.04 |
| Stochastic Oscillator | 0.40 | 76.49 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).